InMed Pharmaceuticals Inc.
INM · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.00 | -0.04 |
| FCF Yield | -179.73% | -182.48% | -164.21% | -118.56% |
| EV / EBITDA | 0.94 | 0.37 | 0.66 | -0.37 |
| Quality | ||||
| ROIC | -54.11% | -80.07% | -67.24% | -139.70% |
| Gross Margin | 34.53% | 23.94% | 33.93% | 49.89% |
| Cash Conversion Ratio | 0.95 | 0.91 | 0.92 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.12% | 61.60% | – | – |
| Free Cash Flow Growth | 18.50% | 6.04% | 52.35% | -59.54% |
| Safety | ||||
| Net Debt / EBITDA | 1.35 | 0.74 | 1.09 | 0.41 |
| Interest Coverage | -20.65 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.35 | 2.81 | 1.69 | 0.22 |
| Cash Conversion Cycle | 101.46 | 92.53 | 166.20 | 915.29 |